Retrospective study of clinical responses to tarlatamab among patients with pulmonary carcinoid

Pulmonary carcinoid (PC) is a well-differentiated neuroendocrine tumor of the lung. In patients with metastatic PC, systemic therapies typically have low response rates, and long-term survival is poor. PC frequently expresses DLL3. A study of 11 patients with DLL3-high PC at Memorial Sloan Kettering Cancer Center (New York, NY) evaluated clinical responses to the DLL3-targeted bispecific T-cell engager tarlatamab. The response rate was 8/11 (73%) and disease control rate was 11/11 (100%). At the time of data cutoff one patient had progressed; median progression-free survival was not reached. Cytokine release syndrome (CRS) occurred in cycle 1 in 9/11 (82%) including 2 with grade 3 CRS. The authors conclude that tarlatamab is a promising treatment option for patients with PC.